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Summary
Background The inappropriate elevation of parathor-
mone (PTH), which regulates the process of angiogen-
esis in parathyroid tissue, causes the changes of activ-
ity of enzymes responsible for the removal of free rad-
icals. Parathyroidectomy (PTX) in patients with pri-
mary hyperparathyroidism (PHPT) lowers the level of
PTH and leads to the reduction of risk of cardiovascu-
lar and all-cause mortality by normalization of the an-
tioxidant status. Therefore, the aims of the study were
to assess the activity of antioxidant enzymes and free
radical reaction products in patients after parathy-
roidectomy, and to evaluate the correlation between
the systemic oxidative stress and angiogenic parame-
ters.
Materials and methods Patients with PHPT treated
surgically were enrolled into the study. Total antiox-
idant capacity (TAC), total oxidative status (TOS),
oxidative stress index (OSI), superoxide dismutase
(SOD), ceruloplasmin (CER), lipid hydroperoxides
(LHP) and malondialdehyde (MDA) were measured
before and after parathyroidectomy. The immunohis-
tological expression of angiogenic factors in parathy-
roid specimens was assessed by the BrightVision
M. Deska · G. Buła · W. Truchanowski · J. Gawrychowski
School of Medicine with the Division of Dentistry,
Department of General and Endocrine Surgery, Medical
University of Silesia, Bytom, Poland
E. Romuk · D. Stolecka · E. Birkner
School of Medicine with the Division of Dentistry,
Department of Biochemistry, Medical University of Silesia,
Zabrze, Poland
O. A. Segiet ()
School of Medicine with the Division of Dentistry,
Department of Histology and Embryology, Medical
University of Silesia, Jordana 19, 41-808 Zabrze, Poland
oliwka.anna@gmail.com
method from ImmunoLogic using murine mono-
clonal anti-human: anti-VEGF, anti-CD31 and anti-
CD106 antibodies.
Results The significant increase of TAC, CER, reduc-
tion of TOS, MDA, SOD, especially for cytoplasmic
form, and significant decrease of OSI, LHP were
observed after PTX. There was no significant corre-
lation between changes of oxidative stress markers
and angiogenic parameters: VEGF, CD-31, CD-106 in
parathyroid tissue. The correlation level was low and
medium.
Conclusions Parathyroidectomy causes down-regula-
tion of lipid peroxidation processes and leads to re-
duction of oxidative stress in patients with PHPT. The
decrease in the OSI is the results of down-regulation
of oxidative stress in the postoperative period. The
change of the antioxidant status has no impact on an-
giogenesis processes in parathyroid tissue.
Keywords Primary hyperparathyroidism · Oxidative
stress · Angiogenesis · Total antioxidant capacity · Total
oxidative status
Introduction
Primary hyperparathyroidism (PHPT) is caused by an
inappropriate elevation of parathormone (PTH) level
by one or more glands, which usually results in hyper-
calcemia [1]. Its prevalence has been estimated to be
0.1–0.3% in the general population and is more com-
mon in women than in men [2]. Excessive secretion
of PTH directly stimulates bone resorption, increases
calcium absorption in the intestine, inhibits the se-
cretion of calcium by the kidney, indirectly enhances
the production of vitamin D, which promotes calcium
absorption in the intestine. Due to the results of stud-
ies revealing the impact of PHPT on the increase of
the incidence of cardiovascular diseases, and prob-
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ably also cancers, in patients with PHPT we should
use surgical treatment [3–5]. Patients with primary
hyperparathyroidism have increased risk of cardiovas-
cular disease, which may be caused by a great number
of factors, such as hypercalcemia [6], low vitamin D
level [7], osteoporosis [8], or hyperphosphatemia [9].
Several studies demonstrated that oxidative stress also
contributed to the development of vascular disorders
[10]. Moreover, circulating oxidized plasma proteins,
known as advanced oxidation protein products, play
a role in the pathogenesis of chronic renal failure [11].
Endothelium is responsible for vascular tone, mainly
due to the production of nitrogen monoxide (NO),
which has been implicated in maintaining the bal-
ance between vasoconstriction and vasodilation. Vas-
cular endothelial cells in diseases, including hyper-
tension, hypercholesterolemia, and diabetes, produce
increased amounts of reactive oxygen species (ROS),
which cause formation of peroxynitrites and therefore
neutralize NO activity. This leads to atherotrombosis
and atherosclerosis [12]. Several reports suggested the
possibility that parathyroidectomy could reduce the
risk of cardiovascular complications [3].
The lack of calcium and phosphate homeostasis
affects the functioning of the body’s defense mech-
anisms, eliminating free radicals, and thereby con-
tributes to the abnormal cell oxidative profile [13].
The imbalance between the intensity of oxidation
processes, which induce the formation of ROS, and
antioxidative defense mechanisms is called oxidative
stress. Parameters used to assess te oxidative stress are
total oxidative status (TOS), total antioxidant capacity
(TAC), and the oxidative stress index (OSI). Total ox-
idative status (TOS) is a parameter, which determines
the total oxidant properties, whereas total antioxidant
capacity (TAC) gives information about the antiox-
idant potential of body fluids in the organism, and
is determined as the moles of oxidants neutralized
by one liter of solution. OSI is defined as the ratio
of the TOS level to TAC level [14]. One of the main
consequences of ROS production is lipid oxidation,
which has been implicated in the pathogenesis of
many diseases. Lipids are oxidized in vivo by several
different oxidants to give diverse products, in gen-
eral lipid hydroperoxides (LHP) as the major primary
product. One of the decay products is malondialde-
hyde (MDA), whose concentration increases due to
enhanced production of ROS; therefore MDA is a lipid
peroxidation marker used to assess lipid peroxidation
caused by increased oxidative stress [15].
Reactive oxygen species can cause the oxidation
of fats, proteins, DNA, and subsequently contribute
to the damage of tissues. Toxic oxidation reaction
products have cytostatic effect due to the cell mem-
branes damage, and lead to cell death by apoptosis
or necrosis. To avoid the mentioned consequences,
in the body there are substances, acting as antiox-
idants, which inactivate and remove ROS. The bal-
ance is maintained by the antioxidant enzymes, such
as superoxide dismutase, catalase, glutathione per-
oxidase, glutathione-S-transferase or non-enzymatic
compounds, such as vitamins A, C, and E, bilirubin,
albumin, uric acid, and ceruloplasmin. Ceruloplas-
min (CER) is an antioxidant, which is responsible for
scavenging ROS such as singlet, superoxide, and hy-
droxyl radicals. This glycoprotein has been impli-
cated in copper transport, iron turnover, ferroxidase,
glutathione peroxidase, and ascorbate oxidase activ-
ities. Its expression has been demonstrated in the
liver, spleen, lung, testis, and brain [16]. Sulfhydryl
(SH) groups, also known as thiol or sulphur groups,
play a huge role in destruction of free peroxidized
fatty acids and hydrogen peroxide. Glutathione (GSH)
is a tripeptide with SH group, and a cosubstrate for
the peroxidation inhibiting protein, which causes de-
composition of hydroperoxide fatty acids located in
phospholipids [17]. Sulfhydryl groups are particularly
susceptible to the effects of free radicals. Several re-
searches indicated that the assessment of the thiol
groups was a better indicator of oxidative stress than
the measurement of the total oxidative status (TOS) or
total antioxidant capacity (TAC) [18]. In most biolog-
ical processes, superoxide anion is the first generated
ROS, which results in the formation of subsequent
ROS. Superoxide dismutase (SOD) is an ubiquitous
enzyme, constituting the first line of defense, which
catalyzes the conversion of superoxide anion into hy-
drogen peroxide and oxygen. There are four families
of SOD, defined by their metal ion binding partners:
Fe, Mn, Ni, or both Cu and Zn. CuZnSOD is a copper
and zinc-containing homodimer that is found almost
exclusively in intracellular cytoplasmic spaces. Mn-
SOD exists as a tetramer and is initially synthesized
with a leader peptide, which targets this manganese-
containing enzyme exclusively to the mitochondrial
spaces. EC-SOD is the most recently characterized
SOD, exists as a copper and zinc-containing tetramer,
and is synthesized with a signal peptide that directs
this enzyme to extracellular spaces [19]. The enzymes
decomposing hydrogen peroxide are catalase (CT) [20]
and glutathione peroxidase (GPx) [21]. Another role of
GPx in defense against ROS is to catalyze the coupling
reaction of products of lipid peroxidation with glu-
tathione aldehyde. By measuring the activity of the
antioxidant system we can indirectly measure free-
radical activity [21].
ROS are also involved in the transmission of sig-
nals, cell differentiation, and apoptosis. They may
affect the functioning of the mechanism of new cells
and blood vessels formation [22]. Hypoxia is a known
factor up-regulating the production of free radicals,
which is also a stimulator of angiogenesis [23]. This
is a multistep process of formation of new blood
vessels from the pre-existing microvasculature, dur-
ing which endothelial cells migrate and proliferate
[23]. Physiologically, it is essential for proper de-
velopment, growth, and maturation of the human
body and is controlled by a balance between pro-
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and anti-angiogenic factors and their receptors. Neo-
vascularization is also implicated in the pathogenesis
of many diseases, particularly neoplasia [24]. Be-
cause the endocrine glands are well vascularized and
the structure of the vessel facilitates the exchange
of various substances, including hormones, they are
a common experimental model in the study on angio-
genesis. Parathyroid tissue can promote spontaneous
induction of angiogenesis in vitro [25] and in vivo
models in a vascular endothelial growth factor-de-
pendent manner [26]. Autotransplanted parathyroid
tissue after thyroidectomy is able to produce new
blood vessels and synthesize parathormone, which
is responsible for maintaining calcium homeostasis
[27]. Several studies demonstrated that also cultured
parathyroid cells could trigger angiogenesis [26]. The
strongest regulator of normal and pathological angio-
genesis is vascular endothelial growth factor (VEGF).
Vascular endothelial growth factor, also known as vas-
cular permeability factor (VPF), plays a huge role in
angiogenesis during embryogenesis, skeletal growth,
and pathological angiogenesis associated with tumor
development. Local hypoxia up-regulates VEGF syn-
thesis [28]. Several studies confirmed its contribution
to the pathogenesis of diseases, such as breast cancer,
renal cell carcinoma, colorectal cancer, angiosar-
coma, rheumatoid arthritis, and diabetic retinopathy
[29–31], Moreover, PTH regulates the expression of
VEGF and metalloproteinases (MMPs) [32, 33].
Platelet endothelial cell adhesion molecule
(PECAM-1), denoted cluster of differentiation 31
(CD31), is a member of type I integral membrane
glycoprotein family. It is expressed on endothelial
cells, peripheral lymphoid cells, platelets, monocytes,
and neutrophils. CD 31 is implicated in angiogenesis,
leukocyte migration, T cell activation, platelet aggre-
gation, regulation of endothelial junctional integrity,
and integrin activation [34, 35].
Vascular cell adhesionmolecule-1 (VCAM-1, CD106)
is present on activated vascular endothelial cells, fol-
licular and interfollicular dentritic cells of lymph
nodes, macrophages myoblasts, and bone marrow
stromal cells. CD106 regulates the adhesion of lym-
phocytes, monocytes, eosinophils, and basophils to
vascular endothelium through interaction with inte-
grin receptors. It is also responsible for transmigration
and co-stimulation of T cell proliferation [36].
The activation mechanism of angiogenesis and ox-
idative stress is still not completely known, but proba-
Table 1 Groupcharacter-
istics
Study group N = 56
Mean age in years 55.6 (28–82)
Sex Male 11 (19.6%)
Female 45 (81.4%)
Histopathology Adenomas 36 (64.3%)
Hyperplasia 17 (30.35%)
Carcinoma 3 (5.35%)
Type of surgery Open parathyroidectomy 56 (100%)
bly it remains under control because most of parathy-
roid tumors are benign and do not have the ability
to metastasize [1, 2]. What is more, of interest is the
impact of systemic oxidative stress occurring in the
PHPT on the severity of angiogenesis in parathyroid
tissue.
Therefore, the aims of the study were the following:
1. Assess the activity of antioxidant enzymes and free
radical reaction products in patients after parathy-
roidectomy;
2. Evaluate the correlation between the systemic ox-
idative stress and angiogenic parameters.
Materials and methods
Blood serum and parathyroid tissue specimens, col-
lected from 56 consecutive patients with PHPT treated
surgically (age 55.66 ± 14.22 years), constituted our
study material (Table 1). Blood samples for biochem-
ical examinations were collected from patients 24 h
before the surgery, as well as on postoperative day 15.
At each time point, 5ml of blood were aspirated into
both vacuum tubes and vacuum tubes with an an-
ticoagulant (EDTA). In order to obtain a hemolysate,
0.9% NaCl was added to the remaining blood cells.
The material was mixed and centrifuged for 10 min
at 3000 revolutions/min. Supernatant was removed
and again 0.9% NaCl was added. The procedure was
repeated twice. Afterward, 0.4ml of blood was col-
lected from the bottom of the test tube and 3.6ml of
doubly distilled water was added. After mixing, we ob-
tained 10% blood cell lysate. The material was frozen
at –80 °C. After thawing, biochemical examinations
were performed.
Biochemical analysis
Analysis of TOS and TAC
The TOS and TAC were determined in serum by the
method described by Erel. TOS measurements were
done by reading at end-point 560 nm in the spec-
trophotometer 3–4 min after mixing the samples and
reagents, and the results were expressed in hydrogen
peroxide liter (µmol H2O2 equiv/l). The method is
based on the oxidation of ferrous ion to ferric ion
in the presence of various oxidant species in acidic
medium and the measurement of the ferric ion by
xylenol orange [37]. TAC was assessed by the use of
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a standard antioxidant solution called Trolox equiv-
alent which is analogous to vitamin E. TAC was pre-
sented as mmol Trolox equiv/l. TAC measurements
were performed by kinetic reading in the spectropho-
tometer 5 min after the sample and reagent were
mixed [38].
Analysis of OSI
After TAC and TOS measurements, the OSI levels,
which allow us to make an exact comment on the
oxidant and antioxidant balance, were calculated
according to the following formula specified in the
catalog of the kit (rel assay diagnostics): OSI = (TOS
µmol/l)/(TAC [mmol Trolox equiv/l] × 100).
Analysis of antioxidants
The method of Oyanagui was used to measure the
activity of superoxide dismutase (SOD) and its isoen-
zymes: the cytoplasmic Cu/Zn-superoxide dismutase
(Cu/ZnSOD) and the mitochondrial Mn-superoxide
dismutase (MnSOD). In this method, xanthine oxi-
dase produces superoxide anions, which react with
hydroxylamine forming nitric ions. This ions react
with naphthalene diamine and sulfanilic acid, gener-
ating a colored product. Concentration of this product
is proportional to the amount of produced superoxide
anions and negatively proportional to the activity of
SOD. The enzymatic activity of SOD was expressed in
nitric units. The activity of SOD is equal to 1 nitric
unit (NU) when it inhibits nitric ion production by
50%. Activities of SOD were normalized to milligram
of protein in homogenates (NU/mg protein) [39]. The
concentration of sulfhydryl groups (SH) in serum was
determined by Koster method using 5,5’-dithiobis(2-
nitrobenzoic acid)—DTNB. Concentration was shown
in mmol/l [40]. Serum ceruloplasmin was determined
spectrophotometrically using the Richterich reaction
with p-phenyldiamine [41].
Analysis of lipid oxidation products
Lipid hydroperoxide concentration in serum was de-
termined by Södergren et al. using xylene orange. Val-
ues were expressed in mmol/l. All this parameters
were measured with the use of the Perkin Elmer spec-
trophotometer Victor X3 [42]. The malondialdehyde
level was determined by the Ohkawa method using
a Perkin Elmer LS45 spectrofluorometer. The concen-
tration of MDAwas expressed as mol/g of protein [43].
Immunohistochemical analysis
For immunohistology, all specimens were immedi-
ately fixed for 20min in cold acetone (–20 °C) and
immersed in embedding medium (OCT Compound,
Miles Inc.), and all of them were cut serially into
5 μm thickness slides, air dried at room temperature,
and assayed. Frozen sections were incubated with
murine monoclonal anti-human: anti-VEGF (clone
SP28), anti-CD31 (clone JC/70A), and anti-CD106
(clone 1.4C3). The dilution of the primary antibod-
ies was 1:500 and was verified in a series of pilot
experiments. The immunohistological investigations
were performed by the BrightVision method from
ImmunoLogic, according to the manufacturer’s in-
structions. The primary antibody was omitted from
negative control slides. The sections were counter-
stained with Mayer’s hematoxylin. Each specimen
was evaluated qualitatively, semiquantitatively (score
index from 0 to 3+), and quantitatively. Semiquan-
titative score index was as follows: (0): no staining;
(1+): weak focal staining; (2+): multifocal moderate
staining; and (3+): diffuse strong staining. Positively
stained cells were counted in all cryostat sections in
at least 10 high power fields (HPF) per each biopsy
under 400x magnification and averaged for each field
using Nikon Eclipse 80i microscope with DSFi1 digital
camera and NIS Elements software form Nikon.
All patients gave their informed consent. The pro-
tocol was approved by the institutional ethics com-
mittee.
Statistical analysis
All statistical analyses were done with the use of STA-
TISTICA 10 program. The normality of the results
distribution was verified using the Shapiro–Wilk test.
Due to the small size of the groups we used non-para-
metric “U”Mann–Whitney test, and the data were pre-
sented as median with the first and fourth quartiles.
The results were considered statistically significant if
p < 0.05. The lack of statistical significance was pre-
sented as NS (nonsignificant).
Results
The activity of antioxidant enzymes and free radical
reaction products in patients before and after
parathyroidectomy
Parathyroidectomy in patients with PHPT resulted in
the significant increase of TAC (p < 0.001) and sub-
stantial reduction of TOS (p = 0.027). Moreover, a con-
siderable decrease in the oxidative stress index (OSI)
was demonstrated (p < 0.05), which was the results
of down-regulation of oxidative stress in postopera-
tive period (Table 2). Among measured antioxidants,
we observed the significant decrease in serum level
of SOD (p < 0.05) mainly in cytoplasmic form CuZn-
SOD (p < 0.05) and the significant increase of ceru-
loplasmin (p < 0.05). The serum concentration of SH
remained unchanged after parathyroidectomy. After
surgery, we observed a significant decrease of lipid
hydroperoxides (p < 0.05) and a decrease of malonic
dialdehyde. Both were caused by down-regulation of
ROS (Table 2). The results are presented in Fig. 1.
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Table 2 Thecomparisonof serumoxidative stress index,
serum level of antioxidants, andserum lipidperoxidase
productsbetweengroupsbefore andafter parathyroidec-
tomy. Parathyroidectomy (PTX) in patientswithPHPT re-
sulted in the significant increaseof TAC (p<0.001) and
substantial reductionof TOS (p=0.027). Moreover, a con-
siderabledecrease in theoxidative stress index (OSI)was
demonstrated (p<0.05),whichwas the results of down-
regulationof oxidative stress inpostoperativeperiod.A sig-
nificantdecrease in serum level of SOD (p<0.05)mainly
in cytoplasmic formCuZnSOD (p<0.05) and the signifi-
cant increaseof ceruloplasmin (p<0.05)wereobserved.
The serumconcentrationofSH remainedunchangedafter
parathyroidectomy. After surgerya significantdecrease
of lipid hydroperoxide (LHP,p<0.05) andadecreaseof
malonicdialdehyde (MDA)weredemonstrated. Bothwere
causedbydown-regulationofROS
Measured parameters Pre-PTX group Post-PTX group
TAC mmol Trolox
equiv/l
0.86 ± 0.15 0.95 ± 0.14*
TOS µmol H2O2
Equiv/L
5.03 ± 1.84 4.49 ± 1.76
OSI AU 584.88 472.62*
SOD NU/ml 14.73 (9.63–20.25) 13.61 (7.4–20.1)
MnSOD NU/ml 7.70 (2.58–16.42) 7.55 (2.51–15.65)
CuZnSOD NU/mg 7.03 (2.9–10.88) 6.06 (0.74–11.83)*
SH umol/g protein 2.72 (0.97–3.79) 2.72 (1.01–4.00)
CER mg/dl 20.49 (5.56–43.22) 24.04 (9.47–58.37)*
LHP mmol/l 3.35 ± 1.83 2.05 ± 1.98*
MDA mol/g of protein 6.24 ± 1.58 5.96 ± 1.54
Mann–Whitney U-test was applied. The data were presented as median
(minimum–maximum) unless stated otherwise
pre-PTX before parathyroidectomy, post-PTX 15 days after parathyroidec-
tomy, TAC total antioxidant capacity, TOS total oxidant status, OSI oxidative
stress index, SOD superoxide dismutase, MnSOD mitochondrial form SOD,
CuZnSOD cytoplasmic form SOD, SH sulfhydryl groups, CER ceruloplasmin,
LHP lipid hydroperoxides, MDA malondialdehyde
*Significant P-value (P < 0.05)
Fig. 1 Thechangesof serumoxidative stress index, serum level of antioxidants, andserum lipidperoxidaseproductsbetween
groupsbefore andafter parathyroidectomy.Mann–WhitneyU-testwasapplied. Thedatawerepresentedasmedian (minimum–
maximum)unless statedotherwise. *SignificantP-value (P<0.05). pre-PTXbeforeparathyroidectomy,post-PTX15daysafter
parathyroidectomy,TAC total antioxidant capacity,TOS total oxidant status,SOD superoxidedismutase,MnSODmitochondrial
formSOD,CuZnSODcytoplasmic formSOD,SH sulfhydryl groups,CER ceruloplasmin,LHP lipid hydroperoxides,MDAmalondi-
aldehyde
The correlation of angiogenesis in the parathyroid
tissue with the parameters of oxidative stress
The expression of angiogenic factors: VEGF, CD31,
CD106 in parathyroid tissue was negatively correlated
with the changes of the TOS, TAC, SOD, and LHP but
positively correlated with MDA. There was no statisti-
cal significance in the study group patients (Table 3).
The correlation level was low andmedium. Among the
studied biochemical parameters, the correlation be-
tween the expression of angiogenic factors with serum
parathyroid hormone is noteworthy (Table 4).
Discussion
Our study demonstrated decreased oxidative stress
markers after parathyroidectomy, which may be one
of the reasons of decreased probability of cardiovascu-
lar events and a survival benefit. In the postoperative
period in patients with primary hyperparathyroidism,
a significant increase of the total antioxidant capacity
and a reduction of total oxidative status were revealed.
Moreover, a considerable decrease in the oxidative
stress index was demonstrated, which was the result
of down-regulation of oxidative stress in postoperative
period. Among measured antioxidants, we observed
a significant decrease in serum level of SOD, mainly
in cytoplasmic form CuZnSOD, which was due to de-
crease in production of superoxide anion, associated
with the normalization of parathormone levels, and
the significant increase of ceruloplasmin. Malondi-
aldehyde concentration in the blood of patients with
primary hyperparathyroidism was reduced, which
was probably triggered by the inhibition of lipid per-
oxidation. These data confirmed the previous study
by Tanaka et al., which showed the case of primary
hyperparathyroidism, in which oxidative stress was
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Table 3 Thecorrelationbetweenstressmarkersandangiogenic factors inparathyroid tissue inpatientswithPHPT.Nosignifi-




TOS TAC SOD LHP MDA
VEGF+ pre-PTX 0.22 0.44 0.05 –0.12 0.13
post-PTX –0.23 –0.17 –0.05 –0.28 0.24
CD31+ pre-PTX 0.29 0.44 0.12 –0.02 0.15
post-PTX –0.42 –0.05 –0.08 –0.37 0.22
CD106+ pre-PTX 0.11 0.33 0.13 –0.03 0.03
post-PTX –0.39 0.06 0.17 –0.36 0.02
Mann–Whitney U-test was applied
pre-PTX before parathyroidectomy, post-PTX 15 days after parathyroidectomy, TAC total antioxidant capacity, TOS total oxidant status, SOD superoxide
dismutase, LHP lipid hydroperoxides, MDA malondialdehyde, VEGF vascular endothelial growth factor, CD31 platelet endothelial cell adhesion molecule,
CD106 vascular cell adhesion molecule-1
Table 4 Thecorrelationbetween thechangesof serum
PTH level andangiogenicparameters inparathyroid tissue.
A strongcorrelationbetweenPTH level and theexpression
of all angiogenesismarkers, includingVEGF,CD31, and
CD106,was revealed,whichproves that parathormone is





27.90 µmol/l ± 32.34
VEGF+ r = 0.65* r = 0.67*
CD31+ r = 0.52* r = 0.36
CD106+ r = 0.50* r = 0.56*
Mann–Whitney U-test was applied
pre-PTX before parathyroidectomy, post-PTX 15 days after parathyroidec-
tomy, VEGF vascular endothelial growth factor, CD31 platelet endothelial
cell adhesion molecule, CD106 vascular cell adhesion molecule-1
*Significant P-value (P < 0.05)
significantly lower after parathyroidectomy [44]. The
results suggest that parathyroidectomy reduces ox-
idative stress in patients with primary hyperparathy-
roidism, which may in part explain reduced risk of
cardiovascular and all-cause mortality after parathy-
roidectomy.
Nevertheless, the reason for decreased oxidative
stress after parathyroidectomy is still not completely
known. We could suspect that the surgery could
cause the changes in oxidative status; however, the
surgery itself is a widely known factor triggering ROS
production [45, 46]. What is more, surgical trauma
is responsible for metastasis development and pro-
motion of tumor growth postoperatively, and this
complication is related to ROS-rich environment in
the postoperative period [47, 48]. On the other hand,
Kaçmaz et al. revealed that nitric oxide and malon-
dialdehyde levels were enhanced and catalase levels
were decreased in patients after both thyroidectomy
and thyroparathyroidectomy [49].
Another factor involved in changes in oxidative
stress could be the level of calcium (Ca). The ex-
cessive accumulation of Ca in mitochondria induces
membrane permeability transition, release of cy-
tochrome c, respiratory inhibition, and ROS produc-
tion. The mitochondrial Ca overload also results
in oxidative stress in cardiomyocytes after ischemia-
reperfusion. Ca overload and oxidative and nitrosative
stress in peripheral blood mononuclear cell (PBMC)
lead to higher production of hydrogen dioxide (H2O2)
and in turn take part in transmitting signals activat-
ing PBMC. Previous parathyroidectomy inhibits ROS
synthesis [13].
Several studies suggested that parathormone could
be the factor implicated in oxidative stress imbalance
and causally involved in pathological processes lead-
ing to cardiovascular disease. After parathyroidec-
tomy, serum PTH decreases rapidly to reach physi-
ological values. Higher plasma PTH was associated
with higher risk for cardiovascular mortality indepen-
dently of established cardiovascular risk factors and
factors associated with mineral homeostasis [50, 51].
Sambrook et al. found that serum PTH was correlated
with increased mortality in the frail elderly, regardless
renal parameters, vitamin D levels, and bone mass as-
sessed by ultrasound examinations [52]. Higher PTH
levels were associated with increased mortality and
severity of illness in critically ill patients in an emer-
gency or intensive care department, independently of
serum calcium levels. Increased PTH concentration
was also correlated with enhanced fatty acid oxida-
tion in the myocardium in animals with secondary
hyperparathyroidism caused by chronic renal failure
[53]. In accordance with this research are the results
of experimental studies which revealed PTH recep-
tors in vascular endothelial cells, suggesting that the
endothelium is a target organ of PTH [54, 55].
There are several possible explanations for the im-
pact of PTH on cardiovascular mortality. PTH is re-
sponsible for regulating the level of ionized calcium
via stimulation of osteoclastic bone resorption, stim-
ulation of calcium reabsorption in the distal tubule
of the kidney, and activation of 25-hydroxyvitamin D
1-alpha hydroxylase in the proximal renal tubule. The
imbalance in mineral homeostasis leads to cardiovas-
cular complications. PTH is also involved in vascu-
lar calcification and remodeling and therefore causes
atherogenesis [56–58]. Excessive levels of PTH result
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in ventricular hypertrophy, cardiac calcification, and
fibrosis [59–61]. Moreover, up-regulated PTH concen-
trations have been implicated in inflammation, raised
systolic blood pressure, and increased body mass in-
dex [4, 62–64]. Therefore, the impact of parathormone
on oxidative stress in patients with primary hyper-
parathyroidism may also be one of the factors impli-
cated in the pathogenesis of cardiovascular complica-
tions in primary HPT.
Oxidative stress also plays a huge role in the pro-
cess of angiogenesis. This process is necessary when
a tumor reaches a critical volume, which is approx-
imately 1–2mm3, in order to continue its expansion
[65, 66]. Nicotinamide adenine dinucleotide phos-
phate oxidases (Nox)-derived ROS and VEGF promote
the angiogenic switch in cancer cells [67, 68]. Nox-de-
rived ROS play a role not only in pathological states,
but also via H2O2 synthesis contribute to the processes
of angiogenesis and tissue repair [69–72]. Reactive
oxygen species stimulate the activation of hypoxia-
inducible factor 1-alpha (HIF-1α) and thus enhance
VEGF expression. When VEGF binds to VEGF recep-
tor 2, it triggers ROS release, which is implicated in
basement membrane degradation, migration, prolif-
eration, and vessel formation [68, 73, 74].
In our study no significant relationship between the
angiogenesis and systemic changes in oxidative stress
in patients who underwent surgery due to primary hy-
perparathyroidism was demonstrated. There was no
significant correlation between the changes in both
the level of antioxidants, as well as lipid peroxida-
tion products and the expression of angiogenic mark-
ers. Nevertheless, endothelial cells are highly hetero-
geneous and it is suggested that the panendothelial
cell markers are not ideal indicators of pathological
or activated neovessels. However, there was a strong
correlation between PTH level and the expression of
all angiogenesis markers, including VEGF, CD31, and
CD106, which proves that parathormone is implicated
in angiogenesis in the parathyroid glands.
In conclusion, this study showed that parathy-
roidectomy was a procedure of a great importance
to reduce oxidation processes in patients with PHPT.
The reduction of the level of parathormone in the
postoperative period plays a crucial role in the down-
regulation of free radical production and lowers the
mortality of patients with PHPT from cardiovascular
diseases. It has not been established what time is
required to obtain a complete normalization of blood
parameters. The mechanism of oxidative stress in the
parathyroid gland is a complex process depending
on many factors, among which of great importance
is PTH. The phenomenon of angiogenesis in the
parathyroid glands is also associated with parathor-
mone, due to the strong correlation between these
parameters. Even if a great number of studies have
been performed recently, the mechanisms implicated
in the pathogenesis of primary hyperparathyroidism
and processes occurring after surgical resection are
still not completely known. A better understanding of
these issues could result in more precise assessment
of diagnosis and more effective treatment, especially
in those cases, in which commonly used parameters
are insufficient. Studies of this type should be con-
tinued and new insight may in the future result in
targeted therapy or possibly prevention.
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